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The enormous benefits of carry reperfusion using thrombolytic 
therapy have been demonstrated repeatedly in patients with 
ST segment elevation who develop Q wave myocardial infarc- 
tion and are treated within 5 h of the onset of symptoms (l-4). 
Retrospective analyses of several individual trials (1,2) and a 
meta-analysis (5) have shown that thrombolytic therapy fails to 
improve clinical outCOme in patients wbo present with ST 
segment depression or develop non-Q wave myocardii infarc- 
tion, or both. Thmmbolytic therapy is thought to be beneficial 
by achieving repemsion of occluded coronary arteries, wbicb 
are present in >9O?G of patients with acute myocardii infarc- 
tion and ST segment elevation (6,7). In contrast, many triak 
have concluded that thmmbolysis is &&rive in patient% with 
myocardial infarction and ST segment depression or T wave 
inversion, or both, because in the majority of such patients the 
infarct-related artery is patent, albeit with a fknv-limiting 
stenosis (8,9). Because thmmbolytii tllkrapy has pmthmm- 
botic potential by activating platelets and exposing clot-bound 
thrombin, it is possible that in these patients the initially 
patent, stenosed coronary artery could pw to occlusion 
with thrombolytic therapy, as was suggested by the TIMI 111 
trial (8,lO). As a consequence, patients with ST segment 
depression, many of whom develop a non-Q wave infarction, 
who comprise almost 50% of all patients with acute myocardial 
‘~farction, have been excluded from reperfnsion therapy. 
Another important group that has been excluded from therapy 
until recently are patients with ST segment elevation who 
present for treatment >6 h after the oMet of chest pain. 
To determine whether eligiiility criteria for thrombolysk 
could be broadened, the Late Asessment of Thrombolytii 
Efficacy (LATE) trial (11) enrolled patients with a myocxdial 
infarction 6 to 24 h after the onset of symptoms. This trial 
inch&d patients with ST seement elevation, ST segment 
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depression and !eft bundle hranrt; block, as well as thou with 
a high likelihood of infarction hut ~.i~hour ST scpment devia- 
tion. A major finding was that treatment with tissue-+ 
plasminogen activator begun 6 to 12 5 after the onset of sump 
toms reduced mortality compared with placebo (11). The LATE 
trial has had a signit%ant impact on c!inical practk. Card&gists 
had been uncomfortable with exclu&~g from thntmht@k tkr- 
apy the large number of patients with ST segment elevation uhu 
presented between 6 and I? h after the onset of pain. Therefore. 
they embraced the results of the LATE trial (11) and the 
fiw trial overvieu (5) to whii the L&TE trial contributed. 
As 3 consequence, the eligiii for thrombolytic therapy of 
patients with ST segment eiaation was extended to thaw pre- 
senting as late as I2 !I after the onset of che5t pain. 
The present rep NI by bagcr et al. (I?). based on subgroup 
analyses of LATE, some of them post hoc (i.e.. data derived), 
provides three major findings that are, respeai+. 1) inter- 
esting but not unexpected, 2) surprising. and 3) prrlvocati\e. 
1. The interesting but not unexpected finding is that pa 
tients who developed a non-Q wave infarction experienced a 
lower mortality than those with a Q wave infarction. This 
observation is consistent with the idea that thmmhdytic ther- 
apy may prevent the evolution of non-Q wave into Q wave 
myocardial infarction because the wavefront of necmsis pro- 
gressing from tbe subendxardium to the s&epicardium is 
interrupted by reperfusiin (13.14). It could be anticipated that 
patients in whom thromhdytic fberapy is socces&l in this 
regard also exhibit superior survival. II would be important IO 
ascertain tither the ditTerence in mortality between Q wave 
and ~91-4 wave infarctions was limited to those patients who 
received the thromboiytic therapy. 
2. The surprising finding is that thrombolytic therapy did 
nol reduce mortality in patients with a myocardial infarction 
presenting with ST segment elevation. As pointed out before. 
many of these patients currently receive such treatment. based 
inpart(andperhapsmistakenly)ontheamch&msoftbe 
LNEtrial(ll).TberqmrtofLangeretal.(I2)qgeststhat 
a more detailed analysis of this patient group is needed to 
discca whether any subgroup of patients with ST segment 
eb&on benefit from thmmbolytic therapy XI h after the 
onset of symptoms. 
3. llte pmvocative finding was that thromboh& therapy 
provided a substantial beneM in the subgroup of f&eats v;ith 
sTsegmentdrprrdon. 
Ifwecombinetheseadditionalana&softheLATEtrial 
with pmious, well established information, it would appear 
that thmmbotyk ttyapy is of benefit in patients with ST 
segment elmtion during the tint 6 h (but not later) and in 
patients with ST segment depessioa >6 h after the onset of 
symptoms(butnotearlier).Ihiipictun=i~puz.&ngandnot 
red!~fzx&wedbyestablkbed~~concepts.it 
issure!ynotinamcertwithcurrentpracGceinwhichthrom- 
bolytk therapy is adminktered 10 patients with a myocardiil 
infarctionwithSTe~tionupto12hafter~oosetofpain 
bntnottopatientswithsrsegrrreotdepresSoairrespmiveof 
0731lW,%~ISsm 
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thetimeaftertheorsetofchestpain.ff,assuggestedbyLanger 
et al (12), thromboIytic therapy is beneficiaI in patients with ST 
seqentdepre&nwhoaretreated>6haftertheometof 
JymptomsisitIo&aItowithhoUitfrompaticntswithST 
segmentdepre&nwhocanhetreatedwithinthetkst6bours? 
Patients with a myocartiai infarction with ST segment 
depression are heterogenecus, and it is possible that a sub 
groupperhaps thnse. with >2 mm ST segment depression, as 
suggested by Langer et al.+ benefited by thrombolytic 
therapy. It is not cIear in how many patients in the JAm trial 
the ST segment depresion was in anterior leads, which might 
act&y represent reciprocal electroxrdiographic changes 
from posteM ST elevation secondary to a totaIIy occluded 
circumfhzx corooaty artery. If improvement in outcome were 
limited to this partkuk subgroup of patients with ST segment 
depression, the Iindmgs of kmger et aI. may be consistent with 
:he current concept that thromboIysis is benelicial onIy in 
patients with some ST segment elevation. 
Ilie interesting retrxpcctive subgroiip anaIyses of Langer 
et al. are of potential importance because the current treat- 
ment of patients with myocardiaI infarcticn and ST segment 
depresb Ieaws much to be desiied. These analyses should 
neither be d&missed simpIy because they do not fit current 
eonqta, nor shouId they form the basis for a sadden radiil 
akation in practice, such as using thromboIytic therapy in 
patients with acute myocardia! infarction and ST segment 
depression. Instead, they suggest that additional prospective, 
rigorously comkted trials of the role of thrombolytic t’lerapy 
in the care of this large segment of patients with acute 
nqvcardii infarction are warranted. 
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